High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status
A Double-Blind, Randomized, Placebo Controlled Trial of High Dose Vitamin D Therapy On Musculoskeletal Symptoms and Bone Mineral Density in Anastrozole-Treated Early Stage Breast Cancer Patients With Marginal Vitamin D Status
Sponsor: AstraZeneca
A EARLY_PHASE1 clinical study on Breast Neoplasms, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed EARLY_PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .